Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
ALS drug from Denali, Sanofi falls short in mid-stage study
Denali Therapeutics and Sanofi's ALS drug failed Phase 2 trial, missing the primary endpoint on the ALSFRS-R scale. Despite the setback, Sanofi continues testing the drug for multiple sclerosis. Denali is also developing another ALS drug, DNL343, targeting nerve cell death mechanisms.
Global Market Pipeline for Vaccine Technologies 2024-2028
The report highlights advancements in vaccine technologies targeting infectious diseases, cancers, and allergies, emphasizing market growth driven by R&D, new product launches, and strategic collaborations. It covers market segmentation, trends, and competitive landscape, offering insights for stakeholders and potential entrants.
Diversity by Design: Combining Strategic Protocol Planning with Accurate Real-world Data
Sanofi collaborates with TriNetX to enhance clinical trial diversity using real-world data, aiming to reduce bias and improve representation. This involves creating patient experience narratives to inform trial design, addressing barriers to participation, and optimizing inclusion criteria. The approach seeks to ensure trials reflect real-world disease distribution across demographics, enhancing research applicability.
First-Line Nivolumab Plus Ipilimumab Shows Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
The CheckMate 8HW trial showed nivolumab plus ipilimumab significantly reduced disease progression or death risk by 79% in MSI-H/dMMR metastatic colorectal cancer patients, compared to chemotherapy. With a 24-month progression-free survival rate of 72% vs 14%, and fewer severe adverse events, this immunotherapy combination may offer a new first-line treatment option.
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss industry
The obesity drug market, led by GLP-1 treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is booming with a projected $100 billion value by 2030. Companies are innovating with new dosages, delivery methods, and exploring additional health benefits. Competition is fierce, with firms like Pfizer and Roche entering the market, while others like Sanofi stay out. The focus is on expanding treatment options and proving efficacy in serious diseases.
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
FDA approved AstraZeneca/Ionis' Wainua for ATTRv-PN, issued a CRL to Merck's gefapixant, and approved Pfizer's Padcev with Merck's Keytruda for bladder cancer. Sanofi halted tusamitamab ravtansine development. Keytruda also gained EU approval for two gastrointestinal cancer indications.
Clarivate Identifies Thirteen Potential Blockbuster Drugs
Clarivate's 2024 Drugs to Watch report highlights 13 new therapeutics expected to achieve blockbuster status by 2029, targeting conditions like sickle cell disease, RSV, and breast cancer. It also notes the growing chronic disease market in China and the impact of new technologies like CRISPR-Cas9 and AI in drug development.
Tonix Pharmaceuticals Appoints Gary Ainsworth as VP of Market Access for TNX-102 SL's Fibromyalgia Treatment
Tonix Pharmaceuticals appointed Gary Ainsworth as VP of Market Access, leveraging his extensive experience for TNX-102 SL's potential fibromyalgia treatment approval by August 15, 2025. Ainsworth's role aims to enhance market access strategies, supporting the drug's commercial launch.
Totus Medicines Closes $66M Series B Funding
Totus Medicines secured $66M in Series B funding led by DCVC Bio, with contributions from North Pond Ventures, Camford Capital, and the University of Minnesota. The funds will advance clinical programs, expand the pipeline, and evolve their AI-driven drug discovery platform. Nassim Usman, Ph.D., was appointed President & CEO, with Neil Dhawan, Ph.D., transitioning to CSO and Head of R&D.
© Copyright 2025. All Rights Reserved by MedPath